Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Vertex Pharmaceuticals
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 4 ans
A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C who Achieve an Extended Rapid Viral Response (eRVR) While Receiving Telaprevir, Peginterferon Alfa2a (Pegasys®) and Ribavirin (Copegus®)
To estimate the difference in SVR rates between T12/PR24 and T12/PR48 treatment regimens in subjects who achieve eRVR.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 4 ans
A study in people with Cystic Fibrosis (a rare hereditary lung disease) to assess the efficacy and safety of a combination of two experimental drugs. Estudio en personas con fibrosis quística (una enfermedad pulmonar hereditaria rara) para evaluar la eficacia y seguridad de una combinación de farmacos experimentales
To evaluate the efficacy of VX-661 in combination with ivacaftor through Week 12 in subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutation on the CF transmembrane conductance...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 4 ans
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation
To evaluate the efficacy of ivacaftor in subjects with cystic fibrosis (CF) who have a non-G551D CFTR gating mutation
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 4 ans
Efficacy of a 12-week Regimen of Telaprevir, Peginterferon, and Ribavirin in Subjects With Interleukin-28B (IL28B) CC Genotype
To evaluate the efficacy of a 12-week regimen of telaprevir, Peg-IFN, and RBV in treatment-naive and prior relapser subjects with genotype 1 CHC and IL28B CC genotype
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 4 ans
A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®), With and Without Ribavirin (Copegus®) in Subjects with Hepatitis C
Primary objective: - To assess the proportion of subjects in each group with undetectable plasma HCV RNA, 24 weeks after the completion of the assigned study drug regimen.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 4 ans
A randomized, double-blind, placebo-controlled, multiple dose study of VX-809 to evaluate safety, pharmacokinetics, and pharmacodynamics of VX-809 in cystic fibrosis subjects homozygous for the deltaF508-CFTR gene mutation
To evaluate the safety and tolerability of VX-809 in CF patients who are homozygous for the DeltaF508-CFTR mutation
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Inc
MAJ Il y a 4 ans
A Phase 1, Randomized, Open-label, Single-Dose, Crossover, Relative Bioavailability, and Food-Effect Study of a Pediatric Chewable Tablet Formulation Relative to a 375-mg Core Tablet Formulation of Telaprevir in Healthy Adult Subjects
- To determine the bioavailability of telaprevir administered as a pediatric chewable tablet formulation relative to a 375-mg core tablet formulation in the fed state - To evaluate the effect of food...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 4 ans
Study to compare the effects of VX-787 with placebo against influenza
The primary objective of the study is to determine the effect of oral administration of VX 787 administered post-inoculation on the AUC of viral titers quantified by nasal swab cell culture in a human...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4